US20080249104A1 - Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide - Google Patents

Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide Download PDF

Info

Publication number
US20080249104A1
US20080249104A1 US10/597,287 US59728708A US2008249104A1 US 20080249104 A1 US20080249104 A1 US 20080249104A1 US 59728708 A US59728708 A US 59728708A US 2008249104 A1 US2008249104 A1 US 2008249104A1
Authority
US
United States
Prior art keywords
salt
methyl
imatinib
phenyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/597,287
Inventor
Hans Michael Burger
Paul William Manley
Michael Mutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080249104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/597,287 priority Critical patent/US20080249104A1/en
Publication of US20080249104A1 publication Critical patent/US20080249104A1/en
Priority to US13/368,811 priority patent/US8513256B2/en
Priority to US13/946,000 priority patent/US20140051853A1/en
Priority to US16/230,676 priority patent/US11612598B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention relates to salts forms of the pharmaceutically active compound 4-[(4-methyl-1-piperazinyl)methyl]-N-[4methyl-3- 4-(3-pyridinyl)2-pyrimidinyl]amino phenyl -benzamide.
  • the pharmaceutically active compound 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide is commonly known by its INN name imatinib. Imatinib and its preparation are described in U.S. Pat. No. 5,521,184.
  • Basic pharmaceutically active compounds are commonly formulated into pharmaceutical preparations as an acid addition salt form, particularly as a crystalline acid addition salt.
  • imatinib is marketed in many countries as its monomethanesulfonate salt (imatinib mesylate) under the brandname GLIVEC or GLEEVEC.
  • GLIVEC monomethanesulfonate salt
  • GLEEVEC GLEEVEC
  • Two crystal forms of imatinib mesylate are described in WO 99/03854.
  • the crystal form designated as the beta form is described as having physical properties that make it advantageous for the manufacture of solid oral pharmaceutical dosage forms, such as tablet and capsule dosage forms.
  • the present invention relates to salt forms of imatinib, other than imatinib mesylate, that are useful for the manufacture of solid or liquid pharmaceutical dosage forms, particularly solid oral dosage forms, such as tablets and capsules, and liquid oral dosage forms, such as orally administered solutions and suspensions, as well as suppositories and other pharmaceutical dosage forms.
  • Each of these salt forms possesses one or more properties that provides advantages when used as a pharmaceutical active ingredient, such as physical properties that make it easier to manufacture one or more dosage forms, improved stability, improved bioavailability and other such properties that are known to one of skill in the art.
  • the salt forms of imatinib are prepared by methods known in the art for making acid addition salts of amines, e.g., by treatment of imatinib with an acid or a suitable anion exchange reagent.
  • imatinib or a solution of imatinib is combined with a solution of an organic or mineral acid in, e.g., a lower alcohol, such as methanol or ethanol, with or without heating.
  • the salt is isolated by crystallization or by evaporation of the solvent and, if desired, purified by re-crystallization from an appropriate re-crystallization solvent by methods known to one of skill in the art.
  • salts for the purpose of administering a salt of 4-[(4methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide by means of an oral solution, in general those salts are preferred having an increased water solubility compared to the free base. Salts having a lower water solubility compared to the free base, render them in general more suitable for the manufacture of sustained release formulations compared to the free base.
  • Important embodiments of this invention include salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3[[4(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide selected from the group consisting of a tartrate salt, such as a (D)( ⁇ ) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, particularly a (S)-lactate salt, a mandelate salt, particularly an (R)(
  • Further important embodiments of this invention include imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate.
  • the acid addition salt is selected from the group consisting of a tartrate salt, such as a (D)( ⁇ ) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a hemiformate salt, a malonate salt, a salicylate salt, a cyclohexanesulfamate salt, a mandelate salt, particularly an (R)( ⁇ ) mandelate salt, a hemiglutarate salt, an adipate salt, a vanillate salt and a sulfate salt.
  • a tartrate salt such as a (D)( ⁇ ) tartrate salt or a (L)(+) tartrate salt
  • a hydrochloride salt such as a citrate salt,
  • the acid addition salt is selected from the group consisting of imatinib D-tartrate, imatinib D-malate, imatinib hemiformate, imatinib malonate, imatinib salicylate, imatinib hemiglutamate, imatinib cyclohexanesulfamate, imatinib mandelate, particularly imatinib (R)( ⁇ ) mandelate, imatinib adipate, imatinib vanillate and imatinib sulfate.
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one of the above mentioned salts of imatinib and a pharmaceutically acceptable carrier.
  • the invention relates to a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide selected from the group consisting of a tartrate salt, such as a (D)( ⁇ ) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt; a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, particularly a (S)-lac
  • the acid addition salt is selected from the group consisting of imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate.
  • the invention relates also to a process for the treatment of warm-blooded animals suffering from a tumour disease, wherein a quantity of one of acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide disclosed herein which is effective against the disease concerned, especially a quantity with antiproliferative and especially tumour-inhibiting efficacy, is administered to warm-blooded animals in need of such treatment, especially the treatment of gliomas, ovarian tumours, prostate tumours, gastro-intestinal stromal tumors, colon tumours, and tumours of the lung, such as especially small cell lung carcinoma, and tumours of the breast or other gynaecological tumours and, in particular leukemia.
  • effective doses for example daily doses of about 10-2000 mg, preferably 25-1000 mg, especially 50-800 mg, are administered to warm-blooded animals of about 70 kg bodyweight.
  • the present invention relates to the use of an acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide according to any one claims 1 to 4 for the manufacture of a pharmaceutical composition for the treatment of a tumour disease, especially the treatment of gliomas, ovarian tumours, prostate tumours, gastro-intestinal stromal tumors, colon tumours, and tumours of the lung, such as especially small cell lung carcinoma, and tumours of the breast or other gynaecological tumours and, in particular leukemia.
  • a tumour disease especially the treatment of gliomas, ovarian tumours, prostate tumours, gastro-intestinal stromal tumors, colon tumours, and tumours of the lung, such as especially small cell lung carcinoma, and tumours of the breast or other gynaecological tumours and, in particular leukemia.
  • Aqueous hydrochloric acid (0.99 g of 37%) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) in ethanol (20 mL).
  • the solution is evaporated to dryness under reduced pressure and the resulting residue is re-crystallized from ethanol ethylacetate.
  • a solution of 4-hydroxy-3-methoxybenzoic acid (vanillic acid; Fluka, Buchs, Switzerland; 694 mg, 4 mmol) in ethanol (50 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The solution is evaporated to dryness under reduced pressure and the resulting residue is re-crystallized from ethanol acetone.
  • a solution of 1,6-hexanedioic acid (adipic acid; Fluka, Buchs, Switzerland; 1081 mg, 4 mmol) in ethanol (80 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.).
  • the hot solution is reduced in volume to 80 mL by rotary evaporation at 90° C. and 400 mbar and then slowly cooled to 20° C.
  • Composition Salt 100 mg Avicel 200 mg PVPPXL 15 mg Aerosil 2 mg Magnesium stearate 1.5 mg 318.5 mg
  • the capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.
  • Solubility in water at room temperature of the 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[ 4 -(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide salts is as listed in Table 1 below.
  • the solubility of the free base in water at room temperature is 0.44 mg/ml.

Abstract

The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-(4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.

Description

  • The present invention relates to salts forms of the pharmaceutically active compound 4-[(4-methyl-1-piperazinyl)methyl]-N-[4methyl-3- 4-(3-pyridinyl)2-pyrimidinyl]amino phenyl -benzamide.
  • The pharmaceutically active compound 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide is commonly known by its INN name imatinib. Imatinib and its preparation are described in U.S. Pat. No. 5,521,184.
  • Basic pharmaceutically active compounds are commonly formulated into pharmaceutical preparations as an acid addition salt form, particularly as a crystalline acid addition salt. For example, imatinib is marketed in many countries as its monomethanesulfonate salt (imatinib mesylate) under the brandname GLIVEC or GLEEVEC. Two crystal forms of imatinib mesylate are described in WO 99/03854. The crystal form designated as the beta form is described as having physical properties that make it advantageous for the manufacture of solid oral pharmaceutical dosage forms, such as tablet and capsule dosage forms.
  • Although it is known that the preparation of salt forms may improve the physical or pharmaceutical properties of a basic pharmaceutically active compound, it is not possible to predict which salt forms may possess advantages for a particular purpose prior to the actual preparation and characterization of the salt form. The present invention relates to salt forms of imatinib, other than imatinib mesylate, that are useful for the manufacture of solid or liquid pharmaceutical dosage forms, particularly solid oral dosage forms, such as tablets and capsules, and liquid oral dosage forms, such as orally administered solutions and suspensions, as well as suppositories and other pharmaceutical dosage forms. Each of these salt forms possesses one or more properties that provides advantages when used as a pharmaceutical active ingredient, such as physical properties that make it easier to manufacture one or more dosage forms, improved stability, improved bioavailability and other such properties that are known to one of skill in the art.
  • The salt forms of imatinib are prepared by methods known in the art for making acid addition salts of amines, e.g., by treatment of imatinib with an acid or a suitable anion exchange reagent. Typically, imatinib or a solution of imatinib is combined with a solution of an organic or mineral acid in, e.g., a lower alcohol, such as methanol or ethanol, with or without heating. The salt is isolated by crystallization or by evaporation of the solvent and, if desired, purified by re-crystallization from an appropriate re-crystallization solvent by methods known to one of skill in the art.
  • For the purpose of administering a salt of 4-[(4methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide by means of an oral solution, in general those salts are preferred having an increased water solubility compared to the free base. Salts having a lower water solubility compared to the free base, render them in general more suitable for the manufacture of sustained release formulations compared to the free base.
  • Important embodiments of this invention include salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3[[4(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, particularly a (S)-lactate salt, a mandelate salt, particularly an (R)(−) mandelate salt, a glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt, particularly an (L)-ascorbate salt and a sulfate salt.
  • Further important embodiments of this invention include imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate.
  • In a preferred embodiment of the present invention, the acid addition salt is selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a hemiformate salt, a malonate salt, a salicylate salt, a cyclohexanesulfamate salt, a mandelate salt, particularly an (R)(−) mandelate salt, a hemiglutarate salt, an adipate salt, a vanillate salt and a sulfate salt.
  • In a further preferred embodiment of the present invention, the acid addition salt is selected from the group consisting of imatinib D-tartrate, imatinib D-malate, imatinib hemiformate, imatinib malonate, imatinib salicylate, imatinib hemiglutamate, imatinib cyclohexanesulfamate, imatinib mandelate, particularly imatinib (R)(−) mandelate, imatinib adipate, imatinib vanillate and imatinib sulfate.
  • The present invention further relates to a pharmaceutical composition comprising one of the above mentioned salts of imatinib and a pharmaceutically acceptable carrier.
  • In one embodiment, the invention relates to a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt; a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, particularly a (S)-lactate salt, a mandelate salt, particularly an (R)(−) mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt, particularly an (L)-ascorbate salt and a sulfate salt.
  • In an important embodiment, the acid addition salt is selected from the group consisting of imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate.
  • The invention relates also to a process for the treatment of warm-blooded animals suffering from a tumour disease, wherein a quantity of one of acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide disclosed herein which is effective against the disease concerned, especially a quantity with antiproliferative and especially tumour-inhibiting efficacy, is administered to warm-blooded animals in need of such treatment, especially the treatment of gliomas, ovarian tumours, prostate tumours, gastro-intestinal stromal tumors, colon tumours, and tumours of the lung, such as especially small cell lung carcinoma, and tumours of the breast or other gynaecological tumours and, in particular leukemia. Depending on species, age, individual condition, mode of administration, and the clinical picture in question, effective doses, for example daily doses of about 10-2000 mg, preferably 25-1000 mg, especially 50-800 mg, are administered to warm-blooded animals of about 70 kg bodyweight.
  • In a further aspect, the present invention relates to the use of an acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide according to any one claims 1 to 4 for the manufacture of a pharmaceutical composition for the treatment of a tumour disease, especially the treatment of gliomas, ovarian tumours, prostate tumours, gastro-intestinal stromal tumors, colon tumours, and tumours of the lung, such as especially small cell lung carcinoma, and tumours of the breast or other gynaecological tumours and, in particular leukemia. The following Examples illustrate the invention without limiting the scope thereof.
    • EXAMPLE 1 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Tartrate
  • 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) is added to a solution of (2R,3R)-2,3-dihydroxybutanedioic acid (L-(+)-tartaric acid; Fluka, Buchs, Switzerland; 1.50 g, 10 mmol) in hot ethanol (40 mL). The solution is evaporated to dryness under reduced pressure and the resulting residue is re-crystallized from methanol to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, tartrate as a pale-yellow crystalline solid, having the following analytical properties: Analysis found: C, 60.18; H, 5.96; N, 14.86%; H2O, 2.25%. Calculated for C33H37N7O7−0.82 H2O: C, 60.19; H, 5.91; N, 14.89%. H2O, 2.24%.
    • EXAMPLE 2 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Hydrochloride
  • Aqueous hydrochloric acid (0.99 g of 37%) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) in ethanol (20 mL). The solution is evaporated to dryness under reduced pressure and the resulting residue is re-crystallized from ethanol ethylacetate. The product is filtered-off and re-crystallized from isopropanol to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, hydrochloride as a pale-yellow crystalline solid, having the following analytical properties: Analysis found: C, 65.27; H, 6.07; N, 18.19; Cl, 6.55%; H2O, 0.56%. Calculated for C29H32N7OCl−0.17 H2O: C, 65.33; H, 6.11; N, 18.39; Cl, 6.65%; H2O, 0.57%.
    • EXAMPLE 3 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Citrate
  • 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) is added to a solution of anhydrous 2-hydroxy-1,2,3-propanetricarboxylic acid (citric acid; Merck, Darmstadt, BRD; 1.92 g, 10 mmol) in methanol (30 mL) at room temperature. Upon cooling, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)2-pyrimidinyl]amino]phenyl]-benzamide, citrate crystallizes and is filtered and dried to afford a pale-yellow crystalline solid, having the following analytical properties: Analysis found: C, 59.24; H, 5.71; N, 13.60%, H2O, 2.14%. Calculated for C35H39N7O80.83 H2O: C, 60.00; H, 5.85; N, 13.99%; H2O, 2.13%.
    • EXAMPLE 4 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Malate
  • 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) is added to a solution of (2S)-(−)-hydroxybutanedioic acid (L-(−)-malic acid; Fluka, Buchs, Switzerland; 1.34 g, 10 mmol) in water (40 mL). The mixture is heated and the resulting hot solution is filtered and evaporated to dryness under reduced pressure to give a residue which is re-crystallized from ethanol, filtered and dried to give 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, malate as a pale-yellow crystalline solid, having the following analytical properties: Analysis found: C, 62.88; H, 6.04; N, 15.60%; H2O, 0.45%. Calculated for C33H37N7O6−0.16 H2O: C, 62.86; H, 5.97; N, 15.55%; H2O, 0.46%.
    • EXAMPLE 5 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]phenyl]-benzamide, Fumarate
  • (Trans)-butenedioic acid (fumaric acid; Fluka, Buchs, Switzerland; 1.16 g, 10 mmol) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) in ethanol (25 mL). The mixture is heated to 90° C., treated with water (18 g) and filtered. Upon cooling, the product crystallizes and is filtered and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, fumarate a pale-yellow crystalline solid, having the following analytical properties: Analysis found: C, 63.91; H, 5.99; N, 15.74%; H2O, 1.27%. Calculated for C33H35N7O5−0.44 H2O: C, 64.18; H, 5.86; N, 15.88%; H2O, 1.28%.
    • EXAMPLE 6 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Succinate
  • 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) is added to a solution of butanedioic acid (succinic acid; Fluka, Buchs, Switzerland; 1.18 g, 10 mmol) is added to a solution of in ethanol (25 mL). The mixture is heated to 90° C., treated with water (0.2 g) and filtered. Upon cooling, the product crystallizes and is filtered and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, succinate as a pale-yellow crystalline solid, having the following analytical properties: Analysis found: C, 64.19; H, 6.11; N, 15.82%; H2O, 0.87%. Calculated for C33H37N7O 5−0.30 H2O: C, 64.23; H, 6.14; N, 15.89%; H2O, 0.88%.
    • EXAMPLE 7 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Benzoate
  • 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) is added to a solution of benzoic acid (Fluka, Buchs, Switzerland; 1.22 g, 10 mmol) in xylene (50 mL). The mixture is heated and the resulting hot solution is filtered. Upon cooling, the product crystallizes and is filtered and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, benzoate as a pale-brown crystalline solid, having the following analytical properties: Analysis found: C, 70.13; H, 6.12; N, 16.24%. Calculated for C35H37N7O3: C, 70.22; H, 6.06; N,15.92%.
    • EXAMPLE 9 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Benzenesulphonate
  • 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) is added to a solution of benzenesulphonic acid (Fluka, Buchs, Switzerland; 1.61 g, 10 mmol) in hot toluene (40 mL). The solution is evaporated to dryness under reduced pressure and the resulting residue is recrystallized from ethanol ethylacetate. The product is filtered-off and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, benzenesulphonate as a pale-yellow crystalline solid, having the following analytical properties: Analysis found: C, 64.19; H, 5.68; N, 14.93; S, 4.87%; H2O, 0.34%. Calculated for C35H37N7O4S−0.12 H2O: C, 64.28; H, 5.74; N, 14.99; S, 4.90%; H2O, 0.33%.
    • EXAMPLE 10 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Pamoate
  • A mixture of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (4.94 g, 10 mmol) and 4,4′-methylenebis[3-hydroxy-2-naphthoic acid (Fluka, Buchs, Switzerland; 3.88 g, 10 mmol) in ethanol (50 mL) is heated. Water (25 mL) is then added. Upon cooling, the product crystallises and is filtered-off and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, pamoate as a pale-yellow solid, having the following analytical properties: Analysis found: C, 69.12; H, 5.62; N, 10.88%; H2O, 2.50%. Calculated for C52H47N7O7−1.26 H2O: C, 69.04; H, 5.52; N, 10.84%; H2O, 2.51%.
    • EXAMPLE 11 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Salicylate
  • A solution of 2-hydroxybenzoic acid (salicylic acid; Fluka, Buchs, Switzerland; 558 mg, 4 mmol) in ethanol (50 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The hot solution is reduced in volume to 80 mL by rotary evaporation at 90° C. and 400 mbar and then slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, salicylate as a crystalline solid, having the following analytical properties: Analysis found: C, 68.18; H, 5.93; N, 15.52; O, 10.42%. H2O, 0.31%. Calculated for C36H37N7O40.11 H2O: C, 68.23; H, 5.92; N, 15.47; O, 10.38%. H2O, 0.31%.
    • EXAMPLE 12 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide Vanillate
  • A solution of 4-hydroxy-3-methoxybenzoic acid (vanillic acid; Fluka, Buchs, Switzerland; 694 mg, 4 mmol) in ethanol (50 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The solution is evaporated to dryness under reduced pressure and the resulting residue is re-crystallized from ethanol acetone. The product is filtered-off and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, vanillate as a crystalline solid, having the following analytical properties: Analysis found: C, 66.61; H, 6.18; N, 14.74; O, 12.86%. H2O, 0.84%. Calculated for C37H39N7O5−0.31 H2O: C, 66.59; H, 5.98; N, 14.69; O, 12.73%. H2O, 0.84%.
    • EXAMPLE 13 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Cyclohexanesulphamate
  • A solution of N-cyclohexylsulphamic acid (Fluka, Buchs, Switzerland; 732 mg, 4 mmol) in ethanol (100 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The solution is evaporated to dryness under reduced pressure and the resulting residue is re-crystallized from ethanol isopropanol. The product is filtered-off and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, sulphamate as a crystalline solid, having the following analytical properties: Analysis found: C, 61.13; H, 6.75; N, 15.87; O, 11.80; S, 4.57%. H2O, 1.69%. Calculated for C35H44N8O4S−0.40 i-PrOH−0.70 H2O: C, 61:28; H, 6.90; N, 15.79; O, 11.50; S, 4.52%. H2O, 1.78%.
    • EXAMPLE 14 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Hemiglutarate
  • A solution of 1,5-pentanedioic acid (glutaric acid; Fluka, Buchs, Switzerland; 539 mg, 4 mmol) in ethanol (60 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The hot solution is reduced in volume to 80 mL by rotary evaporation at 90° C. and 400 mbar and then slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, hemiglutarate as a crystalline solid, having the following analytical properties: Analysis found: C, 64.62; H, 5.81; N, 16.81; O, 11.96%. H2O, 4.14%. Calculated for C32H36N7O3−1.5 H2O: C, 64.74; H, 6.62; N, 16.51; O, 12.13%. H2O, 4.55%.
    • EXAMPLE 15 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Malonate
  • A solution of 1,3-propanedioic acid (malonic acid; Fluka, Buchs, Switzerland; 420.5 mg, 4 mmol) in ethanol (60 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The hot solution is slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, malonate as a crystalline solid, having the following analytical properties: Analysis found: C, 64.0; H, 6.1; N, 16.3; O, 13.6%. H2O, <0.3%. Calculated for C32H35N7O5: C, 64.31; H, 5.90; N, 16.40; O, 13.38%.
    • EXAMPLE 16 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Sulphate
  • A solution of sulphuric acid (Fluka, Buchs, Switzerland; 4.0 mL of 1M) in ethanol (50 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (350 mL at 90° C.). The hot solution is slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl3-[[4-(3-pyridinyl)-2-pyridinyl]amino]phenyl]-benzamide, sulphate as a crystalline solid, having the following analytical properties: Analysis found: C, 55.17; H, 5.82; N, 15.57; O, 18.29; S, 5.26%. H2O, 5.89%. Calculated for C29H33N7O5S−2.06 H2O: C, 55.34; H, 5.95; N, 15.59; O, 17.96; S, 5.10%. H2O, 5.90%.
    • EXAMPLE 17 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Adipate
  • A solution of 1,6-hexanedioic acid (adipic acid; Fluka, Buchs, Switzerland; 1081 mg, 4 mmol) in ethanol (80 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The hot solution is reduced in volume to 80 mL by rotary evaporation at 90° C. and 400 mbar and then slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, adipate as a crystalline solid, having the following analytical properties: Analysis found: C, 64.97; H, 6.33; N, 15.44; O, 12.77%. H2O, 1.43%. Calculated for C35H41N7O5−0.5 H2O: C, 64.76; H, 6.53; N, 15.10; O, 13.61%. H2O, 1.44%.
    • EXAMPLE 18 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, (R)-(−)-mandelate
  • A solution of (R)-(−)-alpha-hydroxybenzeneaceticlic acid ((D)-(−)-mandelic acid; Fluka, Buchs, Switzerland; 553 mg, 3.13 mmol) in ethanol (60 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The hot solution is reduced in volume to 80 mL by rotary evaporation at 90° C. and 400 mbar and then slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, mandelate as a crystalline solid, having the following analytical properties: Analysis found: C, 68.60; H, 6.27; N, 15.19; O, 9.91%. H2O, 0.22%. Calculated for C37H39N7O4−0.08 H2O: C, 68.67; H, 6.10; N, 15.15; O, 10.09%. H2O, 0.22%.
    • EXAMPLE 19 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Malate
  • A solution of (2R)-(−)-hydroxybutanedioic acid ((D)-malic acid; Fluka, Buchs, Switzerland; 553 mg, 2.83 mmol) in ethanol (60 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The hot solution is reduced in volume to 80 mL by rotary evaporation at 90° C. and 400 mbar and then slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)2-pyrimidinyl]amino]phenyl]-benzamide, malate as a crystalline solid, having the following analytical properties: Analysis found: C, 62.14; H, 6.33; N, 15.48; O, 16.18%. H2O, 1.99%. Calculated for C33H37N7O6−0.71 H2O: C, 61.88; H, 6.05; N, 15.31; O, 16.76%. H2O, 2.00%.
    • EXAMPLE 20 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, (D)-(−)-tartrate
  • A solution of (2S,3S)-2,3-dihydroxy-butanedioic acid (tartaric acid; Fluka, Buchs, Switzerland; 606.5 mg, 1.97 mmol) in ethanol (90 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The hot solution is slowly cooled to 20° C. to afford, after filtering and drying, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, tartrate as a crystalline solid, having the following analytical properties: Analysis found: C, 60.54; H, 6.08; N, 14.37; O, 18.89%. H2O, 1.32%. Calculated for C33H37N7O7−0.50 EtOH−0.50 H2O: C, 60.43; H, 6.12; N, 14.51; O, 18.94%. H2O, 1.33%.
    • EXAMPLE 21 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, Hemiformate
  • A solution of formic acid (Fluka, Buchs, Switzerland; 368 mg, 8 mmol) in ethanol (20 mL) is added to a solution of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (1.975 g, 4 mmol) in hot ethanol (150 mL at 90° C.). The solution is evaporated to dryness under reduced pressure and the resulting residue is re-crystallized from acetone. The product is filtered-off and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, hemiformate as a crystalline solid, having the following analytical properties: Analysis found: C, 68.50; H, 6.24; N, 18.93; O, 6.43%. H2O, 1.69%. Calculated for C59H64N14O4−1.80 H2O: C, 68.46; H, 6.25; N, 18.95; O, 6.34%. H2O, 0.17%.
    • EXAMPLE 22Capsules
  • Capsules containing 100 mg of a 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide salt (“Salt”) are usually prepared in the following composition:
  • Composition
    Salt   100 mg
    Avicel   200 mg
    PVPPXL   15 mg
    Aerosil    2 mg
    Magnesium stearate  1.5 mg
    318.5 mg

    The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.
    • EXAMPLE 23Water Solubility
  • Solubility in water at room temperature of the 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4 -(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide salts is as listed in Table 1 below. For comparison, the solubility of the free base in water at room temperature is 0.44 mg/ml.
  • TABLE 1
    Solubility in water at
    Salt of Example room temperature in mg/ml
    1 >51
    2 32.5
    3 38.2
    4 >49
    5 9.71
    6 50.1
    7 47.9
    8 47
    9 >44
    10 0.32
    15 >53

Claims (7)

1. An acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, particularly a (S)-lactate salt, a mandelate salt, particularly an (R)(−) mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt, particularly an (L)-ascorbate salt and a sulfate salt.
2. An acid addition salt selected from the group consisting of imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate.
3. An acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a hemiformate salt, a malonate salt, a salicylate salt, a cyclohexanesulfamate salt, a mandelate salt, particularly an (R)(−) mandelate salt, a hemiglutarate salt, an adipate salt, a vanillate salt and a sulfate salt.
4. An acid addition salt selected from the group consisting of imatinib D-tartrate, imatinib D-malate, imatinib hemiformate, imatinib malonate, imatinib salicylate, imatinib hemiglutamate, imatinib cyclohexanesulfamate, imatinib mandelate, particularly imatinib (R)(−) mandelate, imatinib adipate, imatinib vanillate and imatinib sulfate.
5. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, particularly a D-malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, particularly a (S)-lactate salt, a mandelate salt, particularly an (R)(−) mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt, particularly an (L)-ascorbate salt and a sulfate salt.
6. A pharmaceutical composition of claim 3 wherein the acid addition salt is selected from the group consisting of imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate.
7. Use of an acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide according to claim 1 for the manufacture of a pharmaceutical composition for the treatment of a tumour disease, especially the treatment of leukemia.
US10/597,287 2004-02-04 2005-02-03 Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide Abandoned US20080249104A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/597,287 US20080249104A1 (en) 2004-02-04 2005-02-03 Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide
US13/368,811 US8513256B2 (en) 2004-02-04 2012-02-08 Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
US13/946,000 US20140051853A1 (en) 2004-02-04 2013-07-19 Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
US16/230,676 US11612598B2 (en) 2005-05-26 2018-12-21 Compounds and methods for the treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04
US10/597,287 US20080249104A1 (en) 2004-02-04 2005-02-03 Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide
PCT/EP2005/001077 WO2005075454A2 (en) 2004-02-04 2005-02-03 SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2005/001077 A-371-Of-International WO2005075454A2 (en) 2004-02-04 2005-02-03 SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE
US11/420,425 Continuation-In-Part US20070049602A1 (en) 2005-05-26 2006-05-25 Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
PCT/US2008/061510 A-371-Of-International WO2008134474A2 (en) 2005-05-26 2008-04-25 Compositions and methods including cell death inducers and procaspase activation

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/087,595 Continuation US8592584B2 (en) 2005-05-26 2011-04-15 Compositions and methods including cell death inducers and procaspase activation
US13/087,595 Continuation-In-Part US8592584B2 (en) 2005-05-26 2011-04-15 Compositions and methods including cell death inducers and procaspase activation
US13/368,811 Continuation US8513256B2 (en) 2004-02-04 2012-02-08 Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Publications (1)

Publication Number Publication Date
US20080249104A1 true US20080249104A1 (en) 2008-10-09

Family

ID=34837520

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/597,287 Abandoned US20080249104A1 (en) 2004-02-04 2005-02-03 Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide
US13/368,811 Expired - Fee Related US8513256B2 (en) 2004-02-04 2012-02-08 Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
US13/946,000 Abandoned US20140051853A1 (en) 2004-02-04 2013-07-19 Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/368,811 Expired - Fee Related US8513256B2 (en) 2004-02-04 2012-02-08 Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
US13/946,000 Abandoned US20140051853A1 (en) 2004-02-04 2013-07-19 Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Country Status (22)

Country Link
US (3) US20080249104A1 (en)
EP (1) EP1713792B1 (en)
JP (1) JP4937760B2 (en)
KR (2) KR20060135735A (en)
CN (1) CN100558723C (en)
AR (1) AR047530A1 (en)
AU (1) AU2005211514B2 (en)
BR (1) BRPI0507464A (en)
CA (1) CA2553887C (en)
EC (1) ECSP066752A (en)
IL (1) IL177005A (en)
MA (1) MA28428B1 (en)
MY (1) MY144177A (en)
NO (1) NO20063942L (en)
NZ (1) NZ548714A (en)
PE (1) PE20051096A1 (en)
PH (1) PH12013500157A1 (en)
RU (1) RU2375355C2 (en)
TN (1) TNSN06243A1 (en)
TW (1) TWI347186B (en)
WO (1) WO2005075454A2 (en)
ZA (1) ZA200605972B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054415A1 (en) * 2005-04-13 2009-02-26 Bristol-Myers Squibb Company Combinations, methods and compositions for treating cancer
DE202010017129U1 (en) 2009-01-23 2011-09-14 Teva Pharmaceutical Industries Ltd. Rasagiline formulation with delayed release

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (en) 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
WO2007059963A1 (en) 2005-11-25 2007-05-31 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate
KR100799821B1 (en) * 2007-02-05 2008-01-31 동화약품공업주식회사 Novel imatinib camsylate and method for preparing thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2009036753A2 (en) * 2007-09-20 2009-03-26 Schebo Biotech Ag Novel pharmaceuticals, method for the production thereof and use thereof in medical therapy
BRPI0817946A2 (en) 2007-09-25 2015-05-05 Teva Pharma Stable imatinib compositions
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
TW202241853A (en) 2009-01-16 2022-11-01 美商艾克塞里克斯公司 Pharmaceutical composition comprising malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and use thereof
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2010151689A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2482820A2 (en) 2009-09-28 2012-08-08 Medizinische Universität Wien New use of pdgfrbeta inhibitors
PL389357A1 (en) 2009-10-22 2011-04-26 Tomasz Koźluk Tartaric acids derivatives imatinib salts and process for the preparation thereof
KR101138840B1 (en) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 Imatinib dichloroacetate and anti-cancer agent including the same
KR20130055576A (en) 2010-03-15 2013-05-28 낫코 파마 리미티드 Process for the preparation of highly pure crystalline imatinib base
EP2582689B1 (en) 2010-06-18 2017-03-01 KRKA, D.D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
CA2868381C (en) 2012-04-04 2020-07-07 Intervet International B.V. Soft chewable pharmaceutical products
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
EA035891B1 (en) 2016-01-25 2020-08-27 КРКА, д.д., НОВО МЕСТО Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
US20040048899A1 (en) * 2000-08-04 2004-03-11 Choudary Bernadette Marie Tartrate salts of thiazollidnedione derivative
US7893076B2 (en) * 2005-11-25 2011-02-22 Novartis Ag Crystalline form F of Imatinib mesylate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3691861B2 (en) * 1994-09-14 2005-09-07 株式会社東芝 Optical pulse width control device for optical disk
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
ATE339197T1 (en) * 2002-03-15 2006-10-15 Novartis Ag 4-(4-METHYLPIPERAZINE-1-YLMETHYL)-N-(4-METHYL-3- 4-PYRIMINDINE-3-YL)PYRIMIDINE-2-YL-AMINO)PHENYL)-BENZAMIDE FOR THE TREATMENT OF ANG-II MEDIATED DISEASES
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
US20040048899A1 (en) * 2000-08-04 2004-03-11 Choudary Bernadette Marie Tartrate salts of thiazollidnedione derivative
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
US7893076B2 (en) * 2005-11-25 2011-02-22 Novartis Ag Crystalline form F of Imatinib mesylate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Berge et al., Pharmaceutical Salts, Journal of Pharmaceutical Sciences; Vol. 66, No. 1; January 1977. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054415A1 (en) * 2005-04-13 2009-02-26 Bristol-Myers Squibb Company Combinations, methods and compositions for treating cancer
DE202010017129U1 (en) 2009-01-23 2011-09-14 Teva Pharmaceutical Industries Ltd. Rasagiline formulation with delayed release

Also Published As

Publication number Publication date
AU2005211514A1 (en) 2005-08-18
IL177005A0 (en) 2006-12-10
AR047530A1 (en) 2006-01-25
CA2553887C (en) 2013-04-16
WO2005075454A3 (en) 2006-07-27
TNSN06243A1 (en) 2007-12-03
KR20060135735A (en) 2006-12-29
KR20120127525A (en) 2012-11-21
BRPI0507464A (en) 2007-07-10
JP4937760B2 (en) 2012-05-23
ZA200605972B (en) 2007-11-28
WO2005075454A2 (en) 2005-08-18
EP1713792A2 (en) 2006-10-25
PH12013500157A1 (en) 2014-09-08
NO20063942L (en) 2006-11-02
MY144177A (en) 2011-08-15
RU2006131548A (en) 2008-03-10
RU2375355C2 (en) 2009-12-10
ECSP066752A (en) 2006-11-16
TWI347186B (en) 2011-08-21
US20120142697A1 (en) 2012-06-07
US8513256B2 (en) 2013-08-20
TW200529854A (en) 2005-09-16
US20140051853A1 (en) 2014-02-20
EP1713792B1 (en) 2014-04-30
AU2005211514B2 (en) 2009-09-10
JP2007520518A (en) 2007-07-26
MA28428B1 (en) 2007-02-01
NZ548714A (en) 2009-08-28
CA2553887A1 (en) 2005-08-18
IL177005A (en) 2014-05-28
CN1914191A (en) 2007-02-14
PE20051096A1 (en) 2006-01-23
CN100558723C (en) 2009-11-11

Similar Documents

Publication Publication Date Title
US8513256B2 (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
US9567317B2 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
US9221789B2 (en) Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
EP3287444A1 (en) New crystal form of lenvatinib methanesulfonate salt and preparation method thereof
US9440959B2 (en) Process for the preparation of nilotinib
US8846706B2 (en) Crystalline form K of imatinib mesylate
JP2009542633A (en) Salt of pyrrolopyrimidinone derivative and process for producing the same
JP2012512145A (en) Crystalline salt form of flibanserin
EP2542548A1 (en) Process for preparation of polymorphic form and new polymorphic form of imatinib mesylate isolated in that process
EP2626355B1 (en) Process for the preparation of nilotinib hydrochloride
US10301282B2 (en) Polymorphic form X of nilotinib dihydrochloride hydrate
US20160122315A1 (en) Crystalline imatinib mesylate process
MXPA06008818A (en) Salt forms of 4-(4-methylpiperazin -1-ylmethyl)-n -[4-methyl-3- (4-pyridin-3-yl) pyrimidin-2- ylamino)phenyl]-benzamide
JP2008526862A (en) Preparation of pharmaceutical salts of piperazine compounds
JP2010518072A (en) Novel imatinib cansylate and method for producing the same

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION